Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule

Keyphrases

• Adenoviral 100%
• Epidermal Growth Factor Signaling 100%
• Oncolytic 100%
• Fusion Molecule 100%
• Epidermal Growth Factor Receptor Inhibitors (EGFRI) 100%
• Adenovirus 66%
• Adaptor 66%
• Tumor 33%
• Therapeutic Implications 33%
• Virus 33%
• Tumor Subtype 33%
• Overexpressing 33%
• Poor Prognosis 33%
• Retargeting 33%
• Gene Transfer 33%
• Fold Increase 33%
• Receptor Expression 33%
• Cancer Gene Therapy 33%
• Human Cancer 33%
• Primary Cancer 33%
• Coxsackie-adenovirus Receptor 33%
• Oncolytic Potency 33%
• Metastatic Behavior 33%
• Conditionally Replicative Adenovirus (CRAd) 33%
• Replication-competent 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor 100%
• Epidermal Growth Factor 100%
• Neoplasm 66%
• Adenoviridae 66%
• Malignant Neoplasm 33%
• Primary Tumor 33%
• Gene Delivery 33%
• Coxsackie Virus and Adenovirus Receptor 33%
• Conditionally Replicating Adenovirus 33%
• Virus 33%

Immunology and Microbiology

• Epidermal Growth Factor 100%
• Adenoviridae 75%
• Gene Transfer 25%
• Conditionally Replicating Adenovirus 25%
• Tumor Gene 25%
• Virus 25%
• In Vitro 25%
• Replication 25%